Regenxbio Inc (NASDAQ: RGNX) kicked off on Monday, down -3.15% from the previous trading day, before settling in for the closing price of $7.62. Over the past 52 weeks, RGNX has traded in a range of $7.21-$28.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 72.63% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 21.59%. With a float of $44.85 million, this company’s outstanding shares have now reached $49.53 million.
In an organization with 344 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 39.46%, operating margin of -289.09%, and the pretax margin is -283.37%.
Regenxbio Inc (RGNX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Regenxbio Inc is 9.47%, while institutional ownership is 90.25%. The most recent insider transaction that took place on Oct 01 ’24, was worth 101,052. In this transaction Director of this company sold 10,000 shares at a rate of $10.11, taking the stock ownership to the 11,286 shares. Before that another transaction happened on Sep 03 ’24, when Company’s Director sold 10,000 for $11.56, making the entire transaction worth $115,588. This insider now owns 11,286 shares in total.
Regenxbio Inc (RGNX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.59% per share during the next fiscal year.
Regenxbio Inc (NASDAQ: RGNX) Trading Performance Indicators
Take a look at Regenxbio Inc’s (RGNX) current performance indicators. Last quarter, stock had a quick ratio of 3.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.03, a number that is poised to hit -1.13 in the next quarter and is forecasted to reach -0.96 in one year’s time.
Technical Analysis of Regenxbio Inc (RGNX)
Let’s dig in a bit further. During the last 5-days, its volume was 3.29 million. That was better than the volume of 0.72 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 8.15%. Additionally, its Average True Range was 0.76.
During the past 100 days, Regenxbio Inc’s (RGNX) raw stochastic average was set at 3.63%, which indicates a significant decrease from 6.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 77.50% in the past 14 days, which was higher than the 70.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.53, while its 200-day Moving Average is $13.17. However, in the short run, Regenxbio Inc’s stock first resistance to watch stands at $7.72. Second resistance stands at $8.05. The third major resistance level sits at $8.34. If the price goes on to break the first support level at $7.10, it is likely to go to the next support level at $6.81. Assuming the price breaks the second support level, the third support level stands at $6.48.
Regenxbio Inc (NASDAQ: RGNX) Key Stats
The company with the Market Capitalisation of 365.64 million has total of 49,545K Shares Outstanding. Its annual sales at the moment are 90,240 K in contrast with the sum of -263,490 K annual income. Company’s last quarter sales were recorded 24,200 K and last quarter income was -59,600 K.
